<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147936</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1665-002</org_study_id>
    <nct_id>NCT04147936</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency</brief_title>
  <official_title>A 12-Week, Single-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability, and Physiological Regulation of an Amino Acid Food Product, AXA1665, in Subjects With Mild and Moderate Hepatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blind study to determine whether AXA1665, a composition of
      naturally occuring amino acids, is well tolerated in subjects with mild and moderate hepatic
      insufficiency. Study will also examine how the food product may influence the biology in
      muscle which will be assessed using magnetic resonance imaging (MRI) and other functional
      assessments such as strength, balance and cognition as part of a comprehensive
      physical/neurological exam. Changes in blood biomarkers of inflammation will also be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of study product emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass by MRI</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fischer's ratio [measured by ratio of branched-chain amino acids (leucine, valine, isoleucine) to aromatic amino acids (phenylalanine, tyrosine)]</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma ammonia</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood urea nitrogen concentration</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine concentration</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gait speed</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver Frailty Index</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall physical activity (measured by actigraphy watch)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function measured by the Psychometric Hepatic Encephalopathy Score (PHES)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>AXA1665 29.4g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: AXA1665 Amino acids, food study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1665 53.9 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: AXA1665 Amino acids, food study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 29.4 g</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1665</intervention_name>
    <description>Dietary supplement: AXA1665</description>
    <arm_group_label>AXA1665 29.4g</arm_group_label>
    <arm_group_label>AXA1665 53.9 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo 29.4 g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to participate in the study and provide written informed consent

          -  Male and female adults aged &gt; 18 years

          -  Child-Pugh score ≤9 (i.e. Child-Pugh class A or B)

          -  Liver Frailty Index (LFI) of ≥3.6

          -  Willing and able to engage in 30 minutes of walking/physical activity at least 3 days
             per week

        Exclusion Criteria:

          -  Hospitalization for any complication of cirrhosis or taking new medications intended
             to treat hepatic encephalopathy within 2 months prior to Screening or any
             hospitalization for any cause/reason within 30 days prior to Screening

          -  Prior history or presence of a transjugular intrahepatic portal systemic shunt (TIPS)

          -  Current or history of significant alcohol consumption

          -  Other poorly controlled medical condition [e.g., renal disease with an estimated
             glomerular filtration rate (GFR) &lt;60 mL/min/1.73m2)

          -  Known sensitivity and/or history of clinically significant food intolerance/allergies
             to proteins (including whey, soy, casein, amino acids, etc.)

          -  Any extreme or unbalanced diet such as Ketogenic, Atkins, Paleo, Vegan, etc.

          -  Unable or unwilling to adhere to contraception requirements

          -  Any contraindications to a MRI scan

          -  Any other condition that, in the opinion of the Investigator, renders the subject at
             risk for compliance, compromises the well-being of the subject, or hinders study
             completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun J Sanyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franklin Vairinhos, PhD</last_name>
    <phone>1-857-320-2200</phone>
    <email>regulatory@axcellahealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louisito Valenzuela</last_name>
      <phone>909-203-8459</phone>
      <email>lvalenzuela@catalinari.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madonna Nicolai</last_name>
      <phone>714-210-6640</phone>
      <email>Madonna.Nicolai@OCResearchCenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisa Santana</last_name>
      <phone>305-698-4500</phone>
      <email>fsantana@panaxcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OMEGA Research Maitland, LCC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alma Carmona</last_name>
      <phone>407-988-1075</phone>
      <email>acarmona@omegarcllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avita Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Martinez</last_name>
      <phone>813-603-1800</phone>
      <email>jose@avitaclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Hannasch</last_name>
      <phone>404-532-6840</phone>
      <email>channasch@acmr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandy Cruz</last_name>
      <phone>317-278-6215</phone>
      <email>mandcruz@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Petrus</last_name>
      <phone>318-281-6040</phone>
      <email>cpetrus@gastromds.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Center for Liver Disease</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Schmotzer</last_name>
      <phone>412-802-8567</phone>
      <email>schmotzerar@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Orta</last_name>
      <phone>210-253-3426</phone>
      <email>aorta@txliver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Taylor, MSN</last_name>
      <phone>804-828-9311</phone>
      <email>stephanie.taylor@vcuhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amino acids, food study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

